HC Wainwright Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock

Denali Therapeutics (NASDAQ:DNLI - Free Report) had its target price raised by HC Wainwright from $80.00 to $87.00 in a report released on Friday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Denali Therapeutics' Q1 2025 earnings at ($0.69) EPS, Q2 2025 earnings at ($0.69) EPS, Q3 2025 earnings at ($0.70) EPS and Q4 2025 earnings at ($0.71) EPS.

Several other brokerages also recently issued reports on DNLI. Baird R W raised Denali Therapeutics to a "strong-buy" rating in a report on Tuesday, January 7th. JPMorgan Chase & Co. reduced their price target on shares of Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating for the company in a report on Tuesday, January 7th. Robert W. Baird initiated coverage on Denali Therapeutics in a research note on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 price target for the company. Stifel Nicolaus upgraded Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 price target on the stock in a research report on Monday, December 16th. Finally, The Goldman Sachs Group cut their target price on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.77.

Remove Ads

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI traded up $0.75 during trading on Friday, reaching $15.95. The stock had a trading volume of 2,813,986 shares, compared to its average volume of 1,000,143. The stock has a market cap of $2.30 billion, a PE ratio of -5.78 and a beta of 1.43. Denali Therapeutics has a one year low of $14.08 and a one year high of $33.33. The firm's 50 day moving average price is $21.17 and its two-hundred day moving average price is $24.51.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.75) by $0.08. On average, research analysts expect that Denali Therapeutics will post -2.71 earnings per share for the current year.

Insider Activity

In other news, Director Vicki L. Sato sold 3,080 shares of the business's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the sale, the director now owns 107,976 shares of the company's stock, valued at approximately $2,257,778.16. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Carole Ho sold 12,255 shares of Denali Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $247,796.10. Following the completion of the sale, the insider now owns 178,580 shares of the company's stock, valued at $3,610,887.60. This trade represents a 6.42 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,940 shares of company stock valued at $973,442. 7.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Denali Therapeutics

A number of hedge funds have recently added to or reduced their stakes in DNLI. Polar Asset Management Partners Inc. grew its stake in Denali Therapeutics by 1,240.9% during the fourth quarter. Polar Asset Management Partners Inc. now owns 551,092 shares of the company's stock worth $11,231,000 after buying an additional 509,992 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Denali Therapeutics during the fourth quarter worth $62,000. Woodline Partners LP acquired a new stake in shares of Denali Therapeutics in the 4th quarter valued at $2,038,000. Squarepoint Ops LLC increased its stake in shares of Denali Therapeutics by 44.2% in the 4th quarter. Squarepoint Ops LLC now owns 48,619 shares of the company's stock valued at $991,000 after purchasing an additional 14,896 shares during the last quarter. Finally, Twinbeech Capital LP acquired a new position in shares of Denali Therapeutics during the 4th quarter worth $5,188,000. Institutional investors own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.